<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65451">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913938</url>
  </required_header>
  <id_info>
    <org_study_id>Hemophagocytosis_Ulm</org_study_id>
    <secondary_id>University Ulm</secondary_id>
    <nct_id>NCT01913938</nct_id>
  </id_info>
  <brief_title>Hemophagocytosis in Critically Ill Adult Patients</brief_title>
  <acronym>HCIAP</acronym>
  <official_title>Hemophagocytosis in Critically Ill Adult Patients With Cytopenias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether non-responsiveness to therapeutic
      recombinant human granulocyte colony-stimulation factor (rhG-CSF) is associated with
      hemophagocytosis in critically ill adult patients with cytopenias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In children with bi- or pancytopenia, hemophagocytosis is known as life-threatening
      hemophagocytic lymphohistiocytosis (HLH). The purpose of the study is to find out whether
      adult patients with bicytopenia or pancytopenia fulfilling the clinical HLH criteria used in
      children reflect life-threatening hemophagocytosis and whether hemophagocytosis is
      associated with responsiveness to recombinant human granulocyte colony-stimulation factor
      (rhG-CSF) or not.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>responsiveness to recombinant human granulocyte colony-stimulating factor (rhG-CSF)</measure>
    <time_frame>within 7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>increase in leukocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>8 clinical HLH criteria</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>degree of fulfillment x out of 8 clinical HLH criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>differential blood count, enzymes,biomarkers,immunophenotype</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differential blood count, lactate dehydrogenase, C reactive protein, fibrinogen, triglycerides, ferritin,liver enzymes, aspartate aminotransferase, soluble cluster of differentiation 25, cytokines, procalcitonin biomarkers,immunophenotype (flow cytometry)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hemophagocytosis</condition>
  <arm_group>
    <arm_group_label>patients with cytopenias</arm_group_label>
    <description>Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with leukopenia who are routinely treated with rhG-CSF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  critically ill adult patients

          -  leukopenia and thrombocytopenia

          -  rhG-CSF therapy

        Exclusion Criteria:

          -  life expectancy &lt; 24 hours

          -  inclusion in other studies

          -  trauma patients with reanimation on scene or immediately dying on hospital admission

          -  pregnancy

          -  hematologic disorder, malignancy

          -  high dose corticosteroid treatment or chemotherapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred E Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manfred E Weiss, MD</last_name>
    <phone>49-731-50060226</phone>
    <email>manfred.weiss@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth M Schneider, PhD</last_name>
    <phone>49-731-50060080</phone>
    <email>marion.schneider@uni-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred E Weiss, MD</last_name>
      <phone>49 (0)731-500-60226</phone>
      <email>manfred.weiss@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth M Schneider, PhD</last_name>
      <phone>49 (0)731-500-60319</phone>
      <email>marion.schneider@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bommer, MD</last_name>
      <phone>+49 (731) 500-45530</phone>
      <email>Martin.Bommer@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth M Schneider, PhD</last_name>
      <phone>+49 (731) 500-60080</phone>
      <email>marion.schneider@uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schneider EM, Lorenz I, MÃ¼ller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002 Oct 15;100(8):2891-8.</citation>
    <PMID>12351400</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Manfred Weiss</investigator_full_name>
    <investigator_title>Professor, MD, MBA</investigator_title>
  </responsible_party>
  <keyword>Hemophagocytosis, adults, rhG-CSF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
